Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial-Reference-Cited by-同舟云学术

Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial

Published:2012-10-23 Issue:1 Volume:14 Page:49-59
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Orkin C¹,DeJesus E²,Khanlou H³,Stoehr A⁴,Supparatpinyo K⁵,Lathouwers E⁶,Lefebvre E⁷,Opsomer M⁶,Van de Casteele T⁶,Tomaka F⁸

Affiliation:

1. Barts and The London NHS Trust; London; UK

2. Orlando Immunology Center; Orlando; FL; USA

3. AIDS Healthcare Foundation; Los Angeles; CA; USA

4. Institute for Interdisciplinary Medicine; Hamburg; Germany

5. Chiang Mai University; Chiang Mai; Thailand

6. Tibotec BVBA; Beerse; Belgium

7. Janssen; Tilburg; the Netherlands

8. Tibotec Inc.; Titusville; NJ; USA

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1468-1293.2012.01060.x/fullpdf

Reference18 articles.

1. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2011 www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf

2. European AIDS Clinical Society Clinical management and treatment of HIV-infected adults in Europe 2011 www.europeanaidsclinicalsociety.org/

3. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials;Clotet;Lancet,2007

4. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced HIV-infected patients in TITAN: a randomised controlled phase III trial;Madruga;Lancet,2007

5. Week 48 analysis of once-daily vs twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients;Cahn;AIDS,2011

Cited by 154 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. THERAPEUTIC STRATEGIES AND USE OF LOPINAVIR/RITONAVIR IN PATIENTS WITH HIGHLY RESISTANT HUMAN IMMUNODEFICIENCY VIRUS;FARMACIA;2024

2. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials;The Lancet HIV;2024-02

3. Clinical outcomes with second-line dolutegravir in people with virological failure on first-line non-nucleoside reverse transcriptase inhibitor-based regimens in South Africa: a retrospective cohort study;The Lancet Global Health;2024-02

4. Current antiretroviral therapy: A review;Terapevticheskii arkhiv;2023-12-28

5. 2023 Southern African HIV Clinicians Society Adult Antiretroviral Therapy Guidelines: What’s new?;Southern African Journal of HIV Medicine;2023-09-29